Resistin and Cardiovascular Disease

Parreño, E.; Palomares, Clara; Martínez, Mariana; Ballester, Raul; Martinez, Luz; Fornovi, Aisa

doi:10.4172/2329-9517.1000331

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Resistin is mainly secreted by adipocytes in rodents and in peripheral blood mononuclear cells (PBMC) and macrophages in humans (Parreno et al, 2018 ). It plays an important role in many mechanisms in rodent studies, including insulin resistance, lipid metabolism and inflammation.…”

Section: Assessmentmentioning

confidence: 99%

“…In a systematic review and meta‐analysis, it was shown that in persons with T2DM and obesity, the resistin levels were positively associated with insulin resistance in persons with increased levels of resistin in their blood, but not in those with normal blood resistin levels (Su et al, 2019 ). Serum resistin was involved in the pathogenesis of arteriosclerosis (Parreno et al, 2018 ). In addition, serum resistin levels were increased in patients with hypertension, coronary heart disease and cerebrovascular disease and are related to the development and worsening of heart failure.…”

Section: Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Re‐evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs

Lambré¹,

Baviera²,

Bolognesi³

et al. 2023

EFS2

View full text Add to dashboard Cite

In 2015, EFSA established a temporary tolerable daily intake (t‐TDI) for BPA of 4 μg/kg body weight (bw) per day. In 2016, the European Commission mandated EFSA to re‐evaluate the risks to public health from the presence of BPA in foodstuffs and to establish a tolerable daily intake (TDI). For this re‐evaluation, a pre‐established protocol was used that had undergone public consultation. The CEP Panel concluded that it is Unlikely to Very Unlikely that BPA presents a genotoxic hazard through a direct mechanism. Taking into consideration the evidence from animal data and support from human observational studies, the immune system was identified as most sensitive to BPA exposure. An effect on Th17 cells in mice was identified as the critical effect; these cells are pivotal in cellular immune mechanisms and involved in the development of inflammatory conditions, including autoimmunity and lung inflammation. A reference point (RP) of 8.2 ng/kg bw per day, expressed as human equivalent dose, was identified for the critical effect. Uncertainty analysis assessed a probability of 57–73% that the lowest estimated Benchmark Dose (BMD) for other health effects was below the RP based on Th17 cells. In view of this, the CEP Panel judged that an additional uncertainty factor (UF) of 2 was needed for establishing the TDI. Applying an overall UF of 50 to the RP, a TDI of 0.2 ng BPA/kg bw per day was established. Comparison of this TDI with the dietary exposure estimates from the 2015 EFSA opinion showed that both the mean and the 95th percentile dietary exposures in all age groups exceeded the TDI by two to three orders of magnitude. Even considering the uncertainty in the exposure assessment, the exceedance being so large, the CEP Panel concluded that there is a health concern from dietary BPA exposure.

show abstract

Section: Assessmentmentioning

confidence: 99%

Section: Assessmentmentioning

confidence: 99%

Re‐evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs

Lambré¹,

Baviera²,

Bolognesi³

et al. 2023

EFS2

View full text Add to dashboard Cite

show abstract

“…Подавление инсулинорезистентности, антиатерогенное и противовоспалительное действие не являются класс-специфическими свойствами иАПФ, находясь в тесной ассоциации с гидро-или липофильностью молекулы препарата. Эналаприл и лизиноприл, являясь гидрофильными агентами, не могут обеспечить блокаду РААС висцеральной жировой ткани, следовательно, подавить секрецию адипоцитокинов, реализовать ан тиатерогенное действие [14,15].…”

Section: материал и методыunclassified

Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors

et al. 2020

View full text Add to dashboard Cite

Цель. Оценка возможности азилсартана медоксомила (АЗМ) в достижении целевого артериального давления (АД) (менее 140/90 мм рт.ст.), ангиопротективного действия у пациентов с артериальной гипертензией (АГ), а также снижения уровня адипокинов и маркеров воспаления при переводе пациентов с терапии лизиноприлом или эналаприлом. Материал и методы. В открытое наблюдательное исследование длительностью 24 нед. было включено 60 пациентов, получавших ранее монотерапию оригинальными иАПФ: лизиноприлом 20 мг/сут. или эналаприлом 20 мг/сут., и не достигших целевых уровней АД (<140/90 мм рт.ст.). В ходе исследования всем пациентам проведены суточное мониторирование АД, аппланационная тонометрия (определение индекса аугментации и центрального АД), измерение скорости распространения пульсовой волны, лабораторные тесты (липидный спектр, мочевая кислота, глюкоза натощак, индекс НОМА, гомоцистеин, лептин, адипонектин, высокочувствительный С-реактивный белок (вчСРБ), фактор некроза опухоли альфа, интерлейкин-6 (ИЛ-6).

show abstract

Resistin and Cardiovascular Disease

Cited by 2 publications

References 0 publications

Re‐evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs

Re‐evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs

Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors

Contact Info

Product

Resources

About